Retatrutide Phase 3 Results: What the 2026 Clinical Data Actually Shows

The published retatrutide phase 3 results have, in the span of three months, reshaped what is clinically known about triple-agonist therapy. Two pivotal readouts are now public — one in obesity with knee osteoarthritis, one in type 2 diabetes — and seven additional Phase 3 readouts are expected before the end of 2026. For anyone tracking this compound clinically, the picture is no longer extrapolated from Phase 2. It is being defined in real time by Eli Lilly's TRIUMPH program.

This page is the living clinical reference. It is updated as each readout drops. It does not give dosing, sourcing, or prescription guidance. It gives the data, the context, and the implications for the adult over 40 who is paying attention.

What the Retatrutide Phase 3 Results Show So Far

TRIUMPH-4 — Obesity with knee osteoarthritis (readout: December 11, 2025). A 68-week, randomized, double-blind, placebo-controlled trial in 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. Mean baseline body weight was approximately 112.7 kg. Both the 9 mg and 12 mg weekly doses met all primary and key secondary endpoints. Participants on the 12 mg dose lost an average of 28.7% of body weight (approximately 71.2 lbs) at 68 weeks. WOMAC pain scores were reduced by up to 4.5 points — a 75.8% reduction — and more than one in eight retatrutide-treated patients were completely free of knee pain at trial end. Improvements were also reported across cardiovascular risk markers including non-HDL cholesterol, triglycerides, and systolic blood pressure.

TRANSCEND-T2D-1 — Type 2 diabetes (readout: March 19, 2026). A 40-week Phase 3 trial in adults with type 2 diabetes inadequately controlled by diet and exercise alone, with a mean duration of diabetes of 2.5 years. Retatrutide met the primary and all key secondary endpoints, delivering A1C reductions of up to 2.0% and average weight loss of up to 36.6 lbs (16.8%) on the 12 mg dose. Notably, no weight loss plateau was observed through the 40-week treatment period — participants were still on a downward trajectory at study end. Cardiovascular risk markers improved in line with the obesity readout.

The Receptor Progression Context

Retatrutide is the first investigational triple-hormone receptor agonist to reach late-stage trials. Semaglutide engages one receptor (GLP-1) and produces roughly 15–17% weight loss at peak dose. Tirzepatide engages two (GLP-1 + GIP) and produces roughly 20–22%.

Retatrutide engages three (GLP-1 + GIP + glucagon) and is now producing 24–29% across both Phase 2 and Phase 3 data. The glucagon component is what differentiates retatrutide mechanistically — it adds a direct lipolytic and energy-expenditure signal on top of the appetite and insulin-sensitivity effects of the GLP-1/GIP combination.

This is the clinical context that the TRIUMPH program is now validating at scale.

Safety Signals Worth Understanding

Two findings from TRIUMPH-4 deserve careful attention, because they shape how this compound should be approached by any high-performing adult considering or currently using a research-grade version of it.

Dysesthesia. An abnormal sense of touch was reported in 8.8% of participants on the 9 mg dose and 20.9% on the 12 mg dose, compared to 0.7% on placebo. Lilly characterized most cases as mild, but the magnitude — roughly one in five participants on the highest dose — is a real signal that did not appear at this scale in Phase 2. This is covered in more depth in the existing dysesthesia analysis.

Discontinuation rates and BMI correlation. In TRIUMPH-4, 18.2% of patients discontinued the 12 mg dose due to adverse events, 12.2% on the 9 mg dose, and 4% on placebo. Discontinuation was strongly correlated with baseline BMI — when the analysis was limited to participants with BMI ≥ 35, discontinuation rates dropped substantially. The clinical implication: aggressive dose escalation in lower-BMI users is the tolerability problem, not the compound itself. This is consistent with the recovery-first principle that drives the entire PowerSkulpt approach to peptide-supported protocols — the first 30 days matter more than the next 90.

The 2026 Readout Calendar

Seven additional Phase 3 readouts are expected through the end of 2026.

TRIUMPH-1 — General obesity, 80 weeks. The largest trial in the program and the one that will anchor the weight-management NDA. Designed to be the direct comparator to SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide). Readout expected Q2–Q3 2026. Citi analysts have modeled potential weight loss exceeding 30% given the 80-week duration. This page will be updated within 24 hours of readout.

TRIUMPH-2 — Obesity with type 2 diabetes, 80 weeks. Mirrors TRIUMPH-1 in design but enrolls adults with T2D. Historically, GLP-1-class compounds produce somewhat lower percent weight loss in diabetic populations. Readout expected Q2–Q3 2026.

Maintenance dosing — 4 mg data. Both TRIUMPH-4 and the initial TRANSCEND readouts tested 9 mg and 12 mg only. The 4 mg maintenance dose data is expected in 2026 and will define long-term protocol architecture.

Indication-specific trials. Studies are also underway in moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes (a separate ~10,000-participant CVOT), and metabolic dysfunction-associated steatotic liver disease (MASLD).

Regulatory Status — May 2026

Retatrutide is not approved by the FDA, EMA, MHRA, TGA, or Health Canada. It cannot be legally prescribed for any indication outside of clinical trial enrollment. Eli Lilly's New Drug Application is expected in the Q4 2026 to Q1 2027 window. Assuming standard 10–12 month review, FDA approval is realistically a late 2027 to 2028 event. Lilly has not yet announced a brand name for retatrutide. The company's oral GLP-1 orforglipron — now branded Foundayo — is on a parallel approval track.

Industry analyst GlobalData has forecast peak retatrutide sales of approximately $15.6 billion by 2031, contingent on Phase 3 program completion and timely approval.

What This Means If You're Tracking Retatrutide Clinically

The Phase 3 data does not change anything about legality, sourcing, or prescribability. Retatrutide remains research-grade until at least late 2027. What the data does change is the quality of the conversation around protocol design — dose escalation, tolerability profiling, baseline BMI considerations, and the realistic expectation that meaningful weight reduction continues well past month six rather than plateauing at month three.

For adults over 40 who are currently working with research-grade retatrutide, the most useful clinical takeaways from the Phase 3 data so far are these. Discontinuation is a dose-tolerability and titration problem, not a compound problem. Dysesthesia is real, dose-dependent, and worth screening for. Cardiovascular and metabolic markers improve alongside weight loss in a way that suggests the compound is doing more than reducing appetite. And the weight loss trajectory does not plateau on the timeline most people assume — which has direct implications for how training, recovery, and nutrition should be structured around it.

This is the clinical reasoning behind the PowerSkulpt Retatrutide Troubleshooter — a diagnostic tool that walks through stalled-results scenarios using exactly this framework.

⚠️ This content is for informational purposes only and does not constitute medical advice. Always consult your physician before making changes. PowerSkulpt does not diagnose, treat, or prescribe. Retatrutide is an investigational compound and is not approved by the FDA, Health Canada, or any major regulatory agency as of May 2026.

Training creates the signal. Recovery creates the change.

Most programs start with training. PowerSkulpt starts with recovery.

Stalled on retatrutide? Use the PowerSkulpt Retatrutide Troubleshooter — a free, interactive diagnostic tool that walks through the most common reasons results stall and what to actually do about each one.

Ready for a personal clinical session? The Advanced Consultation is a 60-minute one-on-one ($300 CAD) covering your protocol, your bloodwork, your training, and your recovery architecture. Bring everything. Leave with a plan.

← Back to the PowerSkulpt Method